Article info

Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting
Free

Authors

  1. Correspondence to Dr Nathan Moore, Basingstoke and North Hampshire Hospital, Basingstoke, UK; nathan.moore{at}hhft.nhs.uk
View Full Text

Citation

Moore N, Williams R, Mori M, et al
Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting

Publication history

  • Received June 9, 2021
  • Accepted December 14, 2021
  • First published January 7, 2022.
Online issue publication 
May 18, 2023

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.